Vosaroxin is under clinical development by Denovo Biopharma and currently in Phase III for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase III drugs for Refractory Acute Myeloid Leukemia have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Vosaroxin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vosaroxin overview
Vosaroxin (Voreloxin, Qinprezo) is under development for the treatment of untreated acute myelocytic leukemia and myelodysplastic syndrome (MDS) patients. Vosaroxin is a naphthyridine analog of anticancer quinolone derivative or AQD. It is administered as an intravenous infusion. Vosaroxin acts by targeting DNA and topoisomerase II. The drug candidate was also under development for the treatment of advanced small cell lung cancer, advanced non-small cell lung cancer, and platinum-resistant epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
It was under development for the treatment of glioblastoma multiforme.
Denovo Biopharma overview
Denovo Biopharma is a biotechnology company that provides novel biomarker solutions to personalize drug development. Its pipeline products include DB102- Anti Tumor Drug Enzastraurin, DB104 – Psychiatric Drug Liafensine, is for the treatment of resistant depression, DB107- Anti tumor Gene Therapy Based Drug is for the treatment of gene therapy, DB103- Psychiatric Drug Pomaglumetad Methanoil, DB105 – Psychiatric Drug ORM-12741, DB106 – Antitumor Drug Vosaroxin, DB108 – Anti Tumor Drug Recombinant Endostatin, DB109 – Idalopirdin. It has operations in the US and China. Denovo Biopharma is headquartered in San Diego, California, the US.
For a complete picture of Vosaroxin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
